434 related articles for article (PubMed ID: 19471254)
1. Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis.
Ford AC; Brandt LJ; Young C; Chey WD; Foxx-Orenstein AE; Moayyedi P
Am J Gastroenterol; 2009 Jul; 104(7):1831-43; quiz 1844. PubMed ID: 19471254
[TBL] [Abstract][Full Text] [Related]
2. Effects of 5-hydroxytryptamine (serotonin) type 3 antagonists on symptom relief and constipation in nonconstipated irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials.
Andresen V; Montori VM; Keller J; West CP; Layer P; Camilleri M
Clin Gastroenterol Hepatol; 2008 May; 6(5):545-55. PubMed ID: 18242143
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of 5-hydroxytryptamine 3 receptor antagonists in irritable bowel syndrome: A systematic review and meta-analysis of randomized controlled trials.
Zheng Y; Yu T; Tang Y; Xiong W; Shen X; Jiang L; Lin L
PLoS One; 2017; 12(3):e0172846. PubMed ID: 28291778
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and tolerability of alosetron for the treatment of irritable bowel syndrome in women and men: a meta-analysis of eight randomized, placebo-controlled, 12-week trials.
Rahimi R; Nikfar S; Abdollahi M
Clin Ther; 2008 May; 30(5):884-901. PubMed ID: 18555935
[TBL] [Abstract][Full Text] [Related]
5. Tegaserod for the treatment of irritable bowel syndrome.
Evans BW; Clark WK; Moore DJ; Whorwell PJ
Cochrane Database Syst Rev; 2004; (1):CD003960. PubMed ID: 14974049
[TBL] [Abstract][Full Text] [Related]
6. Tegaserod for the treatment of irritable bowel syndrome and chronic constipation.
Evans BW; Clark WK; Moore DJ; Whorwell PJ
Cochrane Database Syst Rev; 2007 Oct; (4):CD003960. PubMed ID: 17943807
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis.
Ford AC; Talley NJ; Schoenfeld PS; Quigley EM; Moayyedi P
Gut; 2009 Mar; 58(3):367-78. PubMed ID: 19001059
[TBL] [Abstract][Full Text] [Related]
8. Alosetron, cilansetron and tegaserod modify mesenteric but not colonic blood flow in rats.
Painsipp E; Shahbazian A; Holzer P
Br J Pharmacol; 2009 Nov; 158(5):1210-26. PubMed ID: 19785647
[TBL] [Abstract][Full Text] [Related]
9. Alosetron in irritable bowel syndrome: strategies for its use in a common gastrointestinal disorder.
Lembo A; Weber HC; Farraye FA
Drugs; 2003; 63(18):1895-905. PubMed ID: 12930162
[TBL] [Abstract][Full Text] [Related]
10. The risk of ischaemic colitis in irritable bowel syndrome patients treated with serotonergic therapies.
Lewis JH
Drug Saf; 2011 Jul; 34(7):545-65. PubMed ID: 21663331
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of Fecal Microbiota Transplantation in Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis.
Xu D; Chen VL; Steiner CA; Berinstein JA; Eswaran S; Waljee AK; Higgins PDR; Owyang C
Am J Gastroenterol; 2019 Jul; 114(7):1043-1050. PubMed ID: 30908299
[TBL] [Abstract][Full Text] [Related]
12. Effects of linaclotide in patients with irritable bowel syndrome with constipation or chronic constipation: a meta-analysis.
Videlock EJ; Cheng V; Cremonini F
Clin Gastroenterol Hepatol; 2013 Sep; 11(9):1084-1092.e3; quiz e68. PubMed ID: 23644388
[TBL] [Abstract][Full Text] [Related]
13. Pharmacologic Treatments for Irritable Bowel Syndrome: an Umbrella Systematic Review.
Chen M; Tang TC; Qin D; Yue L; Zheng H
J Gastrointestin Liver Dis; 2020 Jun; 29(2):199-209. PubMed ID: 32530987
[TBL] [Abstract][Full Text] [Related]
14. [Antagonists of the type 3 serotonin receptor (5 -HT3) in IBS].
Komoto S; Miura S
Nihon Rinsho; 2006 Aug; 64(8):1487-90. PubMed ID: 16898618
[TBL] [Abstract][Full Text] [Related]
15. Cilansetron: a new serotonergic agent for the irritable bowel syndrome with diarrhoea.
Chey WD; Cash BD
Expert Opin Investig Drugs; 2005 Feb; 14(2):185-93. PubMed ID: 15757394
[TBL] [Abstract][Full Text] [Related]
16. Safety and tolerability of tegaserod in irritable bowel syndrome management.
Berardi RR
J Am Pharm Assoc (2003); 2004; 44(1):41-51. PubMed ID: 14965152
[TBL] [Abstract][Full Text] [Related]
17. Safety profile of tegaserod, a 5-HT4 receptor agonist, for the treatment of irritable bowel syndrome.
Hasler WL; Schoenfeld P
Drug Saf; 2004; 27(9):619-31. PubMed ID: 15230644
[TBL] [Abstract][Full Text] [Related]
18. A randomized, double-blind, placebo-controlled study to assess efficacy and safety of 0.5 mg and 1 mg alosetron in women with severe diarrhea-predominant IBS.
Krause R; Ameen V; Gordon SH; West M; Heath AT; Perschy T; Carter EG
Am J Gastroenterol; 2007 Aug; 102(8):1709-19. PubMed ID: 17509028
[TBL] [Abstract][Full Text] [Related]
19. Systematic review with meta-analysis: the efficacy of prebiotics, probiotics, synbiotics and antibiotics in irritable bowel syndrome.
Ford AC; Harris LA; Lacy BE; Quigley EMM; Moayyedi P
Aliment Pharmacol Ther; 2018 Nov; 48(10):1044-1060. PubMed ID: 30294792
[TBL] [Abstract][Full Text] [Related]
20. Cilansetron: KC 9946.
Drugs R D; 2005; 6(3):169-73. PubMed ID: 15869320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
